Generic protocol for a population-based, age and gender stratified sero-survey study for SARS-CoV-2

  • Version
  • Download 5216
  • File Size 1.17 MB
  • File Count 1
  • Create Date 13 August 2020
  • Last Updated 19 May 2022

Generic protocol for a population-based, age and gender stratified sero-survey study for SARS-CoV-2

Background:

The novel coronavirus disease of 2019 (COVID-19) is a global pandemic, and the epidemic in Africa continues to rise at a rapid rate. Cases have been reported in 54 of 55 member states, most of which already experiencing community-spread hence are making it more difficult to contain the outbreak.

With the expansion of testing, the cumulative number of cases reported in Africa has increased rapidly, however given the fact that majority of cases could be mild or asymptomatic, the true number of infections, their age and sex distribution, and the proportion that are severe or fatal is still uncertain using current surveillance methods.

The number of confirmed COVID-19 cases detected and reported in each country is influenced by many factors including limited access and/or utilization of healthcare and COVID-19 testing, limited surveillance, lack of knowledge amongst the population about when to seek testing, an asymptomatic presentation, and other unknown issues. This is true in all countries of the world, and not Africa specific, however there are factors unique to Africa which may also affect the way the virus behaves there. COVID-19 prevalence data are critical for planning effective mitigation strategies and understandingthe true impact of the disease and relevant intervention measures in Africa, which might be quite different from regions with a different population age distribution or risk factor profile.

Attached Files

FileAction
Generic protocol for a population-based, age and gender stratified sero-survey study for SARS-CoV-2 - ENGLISHDownload

This slide deck, presented at the Developing Countries Vaccine Manufacturers Network International Annual General Meeting in October 2024, describes updated results from a study to assess the current and planned state of vaccine manufacturing in Africa and provides insights into what’s needed to develop a robust and sustainable vaccine manufacturing ecosystem.

We surveyed African vaccine manufacturers to better understand their current manufacturing capacity and capabilities, the progress they’ve made since 2023, and their future outlooks. This information can help stakeholders and funders better coordinate and prioritize actions to build a successful African vaccine manufacturing ecosystem.

Corporate author(s): Africa Centres for Disease Control and Prevention (Africa CDC); Clinton Health Access Initiative (CHAI); PATH

Publication date: October 2024

Download Files
FileAction
African Vaccine Manufacturing Mapping | Supply and Demand LandscapeDownload